Elucidation of a novel mechanism of macrolide resistance in Mycobacterium abscessus

NIH RePORTER · NIH · R21 · $204,155 · view on reporter.nih.gov ↗

Abstract

Project Summary: Mycobacterium abscessus (Mab) is a rapidly growing NTM causing skin and soft tissue infections and pulmonary infections in patients with chronic lung damage, such as prior tuberculosis and cystic fibrosis. Mab stands apart as one of the most antibiotic resistant microbial species, making its infections incredibly difficult to treat. Although macrolides are a cornerstone of therapy against NTMs, they are ineffective against Mab. Intrinsic resistance to macrolides is attributed to macrolide inducible expression of methylases that modify the 23S rRNA comprising the macrolide binding site. To date this is the only known mechanism of macrolide resistance in Mab. We have identified an additional determinant, MAB_3042c, that confers inducible macrolide resistance in Mab. MAB_3042c is homologous to the universally conserved HflX proteins which have been shown to function as ribosome splitting factors. HflX proteins have not been previously implicated in antibiotic resistance suggesting that Mab_3402 could be a novel type of HflX. However, Mab_3402 also shows similarity to ribosome protection factors, which are characterized by an extended loop that inserts into the nascent polypeptide exit tunnel (NPET) and occludes the binding pocket of macrolides. In this project we will explore the function of Mab_3042 in macrolide resistance in Mab. In Aim 1, we will determine the function of MAB_3042c in ribosome splitting and ribosome protection as well as determine the role of these functions in macrolide resistance. In Aim 2 we will study the spectrum of antibiotics that are affected by MAB_3042c. The findings will provide a platform for a long-term structure- function study to gain mechanistic insight into Mab_3402c dependent macrolide resistance in Mab.

Key facts

NIH application ID
9936348
Project number
5R21AI146774-02
Recipient
WADSWORTH CENTER
Principal Investigator
Pallavi Ghosh
Activity code
R21
Funding institute
NIH
Fiscal year
2020
Award amount
$204,155
Award type
5
Project period
2019-06-01 → 2022-05-31